Myriad Genetics (MYGN) Cash from Operations Growth (3y) (2012 - 2026)
Myriad Genetics (MYGN) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn | 11.33% |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn | -9.46% |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn | 20.12% |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn | -11.38% |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn | 11.55% |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn | 35.64% |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn | 24.17% |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn | 5.18% |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn | 10.37% |
| 10 | Myriad Genetics | 296.09 Mn | 171.69 Mn | 137.60 Mn | 22.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.09% |
| Dec 31, 2025 | 51.13% |
| Sep 30, 2025 | 112.06% |
| Jun 30, 2025 | 35.08% |
| Mar 31, 2025 | 29.49% |
| Dec 31, 2024 | 39.16% |
| Sep 30, 2024 | 26.37% |
| Jun 30, 2024 | 37.35% |
| Mar 31, 2024 | -31.21% |
| Dec 31, 2023 | 9.46% |
| Sep 30, 2023 | 28.04% |
| Jun 30, 2023 | -26.39% |
| Mar 31, 2023 | -58.42% |
| Dec 31, 2022 | -31.55% |
| Sep 30, 2022 | -29.61% |
| Jun 30, 2022 | -52.95% |
| Mar 31, 2022 | -108.36% |
| Dec 31, 2021 | -31.06% |
| Sep 30, 2021 | -91.64% |
| Jun 30, 2021 | -27.89% |